Effect of a continuous erythropoietin receptor activator (C.E.R.A.) on stable haemoglobin in patients with CKD on dialysis: once monthly administration

By Locatelli Francesco   Villa Giuseppe   de Francisco Angel L. M.   Albertazzi Alberto   Adrogue Horacio J.   Dougherty Frank C.   Beyer Ulrich    

Current Medical Research and Opinion, Vol. 23, Iss. 5, 2007-05 ,pp. : 969-979

Informa Healthcare

Access to resources Recommend Favorite

Comparing the efficacy of continuous erythropoietin receptor activator and darbepoetin Alfa treatments in Japanese patients with chronic kidney disease during the predialysis period: A propensity‐matched analysis

By  

NEPHROLOGY, Vol. 20, Iss. S4, 2015-12 ,pp. : 22-28

John Wiley & Sons Inc

Access to resources Recommend Favorite

A randomised, cross-over study comparing injection site pain with subcutaneous epoetin beta and subcutaneous darbepoetin alfa in patients with chronic kidney disease

By Roger Simon D.   Suranyi Michael G.   Walker Rowan G.    

Current Medical Research and Opinion, Vol. 24, Iss. 8, 2008-08 ,pp. : 2181-2187

Informa Healthcare

Access to resources Recommend Favorite

Evaluation of maintenance of stable haemoglobin levels in haemodialysis patients converting from epoetin or darbepoetin to monthly intravenous C.E.R.A.: the MIRACEL study

By Fliser D.   Kleophas W.   Dellana F.   Winkler R.E.   Backs W.   Kraatz U.   Fassbinder W.   Wizemann V.   Strack G.  

Current Medical Research and Opinion, Vol. 26, Iss. 5, 2010-05 ,pp. : 1083-1089

Informa Healthcare

Access to resources Recommend Favorite

Erythrocyte Indices in the Assessment of Iron Status in Dialysis-Dependent Patients with End-Stage Renal Disease on Continuous Erythropoietin Receptor Activator versus Epoetin β Therapy

By  

Acta Haematologica, Vol. 124, Iss. 1, 2010-07 ,pp. : 27-33

Karger

Access to resources Recommend Favorite